PH, 2 as severe PH has been associated with decreased posttransplant survival and increased post-transplant cardiovascular complications. 4 A previous study reported that in patients undergoing pretransplant evaluation with transthoracic echocardiography (TTE), PH has been detected in 17% of patients with a mean pulmonary arterial systolic pressure (PASP) of 45.9 ± 8.8 mm Hg. 5 Despite the high prevalence of PH in end-stage renal disease patients considered for kidney transplantation, data on post-transplant outcomes in patients with pretransplant mild-to-moderate PH are very limited. In this study, we evaluated effects of mild-to-moderate pretransplant PH on mortality and graft loss over the mean follow-up of 4 years, and the renal graft function at 1 and 2 years after renal transplantation.
| MATERIAL S AND ME THODS

| Study design
This 
| Patient population
Demographic and clinical information was collected from electronic medical records. Demographic characteristics included age at the time of transplant, ethnicity, and gender. Each patient was also assessed for the presence of comorbidities including hypertension, diabetes mellitus, history of myocardial infarction, hypothyroidism, chronic obstructive pulmonary disease, coagulopathy, atrial fibrillation, gout, tobacco, and alcohol use. The etiologies of renal failure were identified. Kidney allografts were grouped as live vs cadaveric donors.
| Echocardiographic data
Preoperative TTE was performed utilizing commercially available echocardiographic equipment in an Inter-societal Accreditation
Commission accredited echocardiographic laboratory. PASP was assessed as recommended in the 2011 "American Society of
Echocardiography Guidelines for the echocardiographic assessment of the right heart in adults". 6 The highest tricuspid regurgitant ve- 
| Clinical outcomes
The following outcomes were analyzed in the study: immediate posttransplant length of hospital stay, post-transplant renal allograft functions as assessed by 1-and 2-year serum creatinine (Cr), and estimated glomerular filtration rate (eGFR). Recipient mortality and etiology, and the rate of graft loss over the mean follow-up period of 4.0 ± 1.9 years were also calculated.
| Statistical analysis
Continuous variables are presented as mean with standard deviation, and categorical variables as percentages. Differences between patients with normal and elevated PASP were examined by Student's t test for continuous variables and chi-square test for categorical variables. For statistically significant differences between the groups, multivariate regression analysis was used to adjust for confounding variables. All statistical analyses were performed using Stata software, version 14.0 (Stata Corp, College station, Texas).
A P-value of 0.05 was considered as statistically significant. All Pvalues were two-tailed. Graft loss and mortality were evaluated with Kaplan-Meier survival analysis.
| RE SULTS
| Baseline characteristics of the study population
The majority of the recipients were Caucasian (81.3%), males (63.5%), 50.9 ± 12.4 years at the time of the surgery and received deceased-donor renal transplant (81.8%). End-stage renal disease was most frequently due to diabetes mellitus and/or hypertension (44.5%), followed by polycystic kidney disease (15.7%) and glomerular diseases (8.9%).
Among 192 patients included in the study, 51 (27%) had elevated PASP. The mean PASP in the normal pressure group was 26.98 ± 5.43 mm Hg and in the elevated pressure group was 46.35 ± 9.50 mm Hg (P < 0.001) ( 
| Graft function at 1 year post-transplant
One-year outcomes were available for 192 patients and are presented in Table 2 and Figure 1 . At 1 year post-kidney transplant, when 
| Graft function at 2 years post-transplant
Of the 192 study patients, 2-year outcomes were available for 175 post-transplant patients and are presented in Table 3 and Although the mean serum Cr was higher in the elevated PASP (1.44 mg/dL) as compared to the normal PASP (1.25 mg/dL), the difference did not reach statistical significance, P = 0.09 ( Figure 1 and Table 2 ). In the multivariate logistic regression analysis adjusted for the presence of depressed left ventricular ejection fraction, each 1 mm Hg increase in PASP was associated with 8.940 mL/min decrease in eGFR (95% CI −15.772 to −2.108, P = 0.011).
| Other clinical outcomes
During the mean follow-up of 4.0 ± 1.9 years, among all 192 study patients, the mortality rate was 5.7%. Most of the deaths occurred after 2 years post-transplant in both groups, most commonly due TA B L E 2 Outcomes at 1 and 2 y after renal transplantation F I G U R E 1 Preoperative pulmonary arterial systolic pressure is associated with decline in renal function (estimated glomerular filtration rate) at 1-and 2-y follow-up to cardiovascular disease, followed by malignancy. There were no differences in the graft loss rates (combined mortality and graft loss without mortality) attributable to PASP. Mean time to graft loss was 27 ± 10.7 months in patients with elevated PASP and 33 ± 17.6 months in patients with normal PASP (P = 0.984, Figure 2 ).
| D ISCUSS I ON
This is the largest study to date that examined the effects of mild-tomoderate PH on renal transplant outcomes. Several relevant findings were identified. The overall prevalence of elevated pulmonary pressure among patients undergoing renal transplantation in our analysis was 26.6%. This rate is similar to previous studies examining the prevalence of PH in end-stage renal disease patients. Prior analysis has demonstrated that PH is common among patients with chronic kidney disease and in patients receiving hemodialysis. 10 3 and potential repeated microair bubble pulmonary embolism. 16 Additionally, impaired diastolic dysfunction as reflected by left ventricular hypertrophy has also been proposed to play a role in the development of PH. 17 Etiology of PH in chronic kidney disease is likely multifactorial in nature, and in accord with that, in our study, elevated pulmonary pressure was more common in patients with left ventricular systolic dysfunction although the overall prevalence of left ventricular systolic dysfunction was low.
When found in patients with chronic kidney disease, PH is an independent risk factor for death (HR 1.38; 95% CI 1.10-1.72) and cardiovascular events (HR 1.23; 95% CI 1.00-1.52), 11 and is a common cause for deferring kidney transplantation. 18 In fact, renal transplantation is limited in uncorrectable moderate-to-severe PH, 2 as severe PH has been associated with decreased post-transplant survival and increased post-transplant cardiovascular complications. 4 Our findings indicate that mildly to moderately elevated pulmonary pressure does not increase 4-year rates of graft loss or death but is associated with decreased eGFR at 1 and 2 years. However, the decreased eGFR in In contrast to that, in our study of the patients who underwent renal transplant between 2008 and 2015, the short-term graft loss and mortality rates were much lower for the overall cohort (9.8%) and were not significantly affected by elevated pulmonary pressure. It is tempting to attribute the improved outcome to the quality and consistency of care, as the overall mortality and graft loss rate among patients undergoing renal transplant in our medical center is among the lowest in the US. 20 However, it may also be due to advances in patient care, meticulous TA B L E 3 Multivariate analysis of renal function adjusted for left ventricular ejection fraction F I G U R E 2 Kaplan-Meier curve on post-transplant survival based on pulmonary artery systolic pressure patient selection and follow-up care, and unidentified comorbidities.
In any case, our study cohort is significantly larger and represents the patient sample treated more recently.
There are several limitations to our study. This is a single-center retrospective analysis performed at a medical center. However, as attested by the reported outcomes, all patients enrolled in the current study consistently received the highest quality of care with excellent outcomes. 20 Secondly, as the severe PH with PASP > 80 mm Hg is a contraindication for renal transplantation at our center, only patients with mild and moderate PH were included in this study, and our findings can only be applied to the studied group. Furthermore, patients were defined to have PH solely by noninvasive assessment, without confirmation by invasive measurements. However, this reflects the real-world evaluation of these patients.
| CON CLUS IONS
In conclusion, pretransplant mild-to-moderate elevation in PASP estimated by TTE is associated with significantly lower renal transplant function at 1 and 2 years, but does not have a significant effect on short-term graft loss and mortality. Obtaining PASP in every patient noninvasively prior to renal transplantation could be of important prognostic value, especially if long-term analysis shows decreased graft survival in high PASP patients. Larger and longer-term prospective studies are needed to more precisely assess the effect of PH in renal transplant recipients.
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